Collegium Pharma (NASDAQ: COLL) reported Q1 EPS of $1.76, $0.13 better than the analyst estimate of $1.63. Revenue for the quarter came in at $193.52 million versus the consensus estimate of $187.37 million.

GUIDANCE:

Collegium Pharma sees Q2 2026 revenue of $190-200 million, versus the consensus of $196.9 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.